Viewing data from:

YARTEMLEA

BLA

NARSOPLIMAB-WUUG | B761152 | OMEROS CORP

1 product0 Purple Book patents

Biologic LOEProtected

Estimated date when biosimilar competition may begin

December 23, 2037(4191 days remaining)

Regulatory Exclusivities

Type	Expiry	Status	Source
12-Year BPCIA	Dec. 23, 2037	Active	Computed

Purple Book Patents

No listed patents in Purple Book.

Estimated Patent LOE

Oct. 24, 20446688 days remaining

Based on latest discovered patent 12129290(diagnostic) · relevance 95/100

Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.

Discovered Patents

View all 1 patents →

1 AI-discovered patents, sorted by relevance.

Diagnostic

(1)

95/10012129290Grant: 2024-10-29 | Exp: 2044-10-24

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 761152

351(a) ReferenceLicensedCDERInjection

Proper Name

narsoplimab-wuug

Applicant

Omeros Corporation

Approval Date

23-Dec-25

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Dec 29, 2025	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — N/A

▴

INJECTION | Approved: 2025-12-23 00:00:00

No patent or exclusivity listings for this strength.